VERA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
10.3M
0
0
0
0
Cost of Revenue
3.3M
0
0
0
0
Gross Profit
7.0M
0
0
0
0
Operating Expenses
102.7M
-8.7%
112.5M
-10.1%
125.1M
+32.8%
94.2M
+12.2%
83.9M
R&D
41.3M
-31.3%
60.1M
-30.1%
86.0M
+45.0%
59.3M
+5.0%
56.5M
SG&A
61.4M
+17.2%
52.4M
+34.0%
39.1M
+12.1%
34.9M
+27.1%
27.5M
Operating Income
-95702000
+14.9%
-112490000
+10.1%
-125132000
-32.8%
-94206000
-12.2%
-83932000
EBITDA
-94879000
+15.6%
-112358000
+10.1%
-124992000
-32.9%
-94071000
-12.3%
-83803000
Net Income
-93711000
+14.6%
-109720000
+10.0%
-121974000
-33.9%
-91097000
-13.5%
-80293000
EPS (Basic)
$-1.30
+14.5%
$-1.52
+10.1%
$-1.69
-21.6%
$-1.39
-10.3%
$-1.26
EPS (Diluted)
$-1.30
+14.5%
$-1.52
+10.1%
$-1.69
-21.6%
$-1.39
-10.3%
$-1.26
Shares (Diluted)
72.1M
+0.4%
71.8M
+0.5%
71.5M
+8.9%
65.6M
+2.8%
63.8M
Vera Therapeutics (VERA) — Financials